Abstract High-dose methotrexate (HDMTX), defined as a dose higher than 500 mg/m2, is
used to treat a range of adult and childhood cancers. Although HDMTX is safely …

More is known about the metabolism, toxicity, pharmacokinetics, and clinical profile of
methotrexate (MTX) than any other drug currently in use in either rheumatology or oncology …

Severe adverse systemic drug events occur commonly as a result of treatment of cancer
patients. Nephrotoxicity of chemotherapeutic agents remains a significant complication …

Purpose High-dose methotrexate (HD-MTX) is widely used in pediatric and adult oncology
treatment regimens. This study aimed to develop a population pharmacokinetic model to …

The quantitative aspects of drug disposition in man of the commonly used antineoplastic
agents, including cyclophosphamide, the nitrosoureas, cisplatin, methotrexate, cytarabine, 5 …

Limited penetration of anticancer drugs through tumour tissue is an important factor that may
limit therapeutic effects against solid tumours. Here we report studies of the penetration of …

Methotrexate, when used in high doses (12 g/m 2) in the treatment of osteosarcoma, shows
wide between-subject variability (BSV) in its pharmacokinetics. High-dose methotrexate is …

PURPOSE Pharmacokinetics, toxicity, and therapeutic efficacy of two different methotrexate
(MTX) infusions for remission induction of relapsed childhood acute lymphoblastic leukemia …

Therapeutic drug monitoring is now widely used in many areas of medicine. With its
proliferation has come an understanding of the clinical situations in which it is likely to be of …

Numerous studies have found a clear relationship between systemic exposure and the
toxicity or (more rarely) the efficacy of anticancer agents. Moreover, the clearance of most of …